Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894699 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure
A Phase 2 study, sponsored by Talphera.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00894699 is a Phase 2 study that has completed, run by Talphera. The registered enrollment target is 40 participants.
The verdict
NCT00894699, a Phase 2 study, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of a study medication that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This drug is being designed to provide mild sedation as well as reduce anxiety and pain before and during a procedure (in this case elective abdominal liposuction).
Interventions
- DRUG Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
- DRUG Placebo NanoTab™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00894699
The ClinicalTrials.gov registry entry for NCT00894699 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03) is the first listed.
NCT00894699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00894699 about?
NCT00894699 is a clinical study titled "A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure". The purpose of this study is to evaluate the safety and effectiveness of a study medication that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This drug is being designed to provide mild sedation as well as reduce anxiety and pain before and during a procedure (...
What is the current status of trial NCT00894699?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2009-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00894699?
The interventions under investigation include: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03) (DRUG), Placebo NanoTab™ (DRUG).
Who is sponsoring clinical trial NCT00894699?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.